Showing 1581-1590 of 2157 results for "".
- AAD 2026: Lumenis Launches triLIFT 2.0 for Combined Muscle and Skin Rejuvenationhttps://modernaesthetics.com/news/lumenis-launches-trilift-20-for-combined-muscle-and-skin-rejuvenation/2486430/Lumenis Be Ltd. announced the commercial launch of triLIFT 2.0, a next-generation platform designed to deliver combined muscle stimulation and skin rejuvenation for facial and body applications. The system integrates Dynamic Muscle Stimulation technology (DMSt) with FibroBoost, aiming to address
- AAD 2026: CO2 Laser Resurfacing Linked to Transient Microbiome Shiftshttps://modernaesthetics.com/news/aad-2026-co2-laser-resurfacing-linked-to-transient-microbiome-shifts/2486399/New findings presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, provide insight into dynamic microbiome changes following ablative CO2 laser resurfacing and their relationship to wound healing. In this monocentric, double-blind, rando
- AAD 2026: Survey Highlights Facial Concerns Among GLP-1 Weight Loss Patientshttps://modernaesthetics.com/news/aad-2026-survey-highlights-facial-concerns-among-glp-1-weight-loss-patients/2486397/A large survey presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, highlights evolving aesthetic concerns among patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss. The analysis, based on responses from 406 US healthcare
- AAD 2026: Revance to Showcase Expanding Aesthetics Portfoliohttps://modernaesthetics.com/news/aad-2026-revance-to-showcase-expanding-aesthetics-portfolio/2486383/Revance Therapeutics Inc. announced it will showcase its expanding portfolio of aesthetics, regenerative medicine, and consumer skincare products at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 26–31 in Denver, Colorado. The company plans a series of in-booth
- Lynch Regenerative Medicine Expands PDGF Portfolio With GEM 21S® Distribution Agreementhttps://modernaesthetics.com/news/lynch-regenerative-medicine-expands-pdgf-portfolio-with-gem-21s-distribution-agreement/2486379/Lynch Regenerative Medicine, LLC (LRM) announced a definitive distribution agreement with Lynch Biologics, a Geistlich North America company, to commercialize GEM 21S®, an FDA-approved recombinant human platelet-derived growth factor (rhPDGF-BB) product, to licensed healthcare providers in the Un
- FDA Approves Restylane Contour for Temple Hollowing Correctionhttps://modernaesthetics.com/news/fda-approves-restylane-contour-for-temple-hollowing-correction/2486354/Galderma announced that the U.S. Food and Drug Administration (FDA) has approved Restylane® Contour™ for the correction of temple hollowing in patients aged 21 years and older, expanding its indications beyond cheek augmentation and midface contour deficiencies. The approval enables clinicians to
- Revance, Teoxane Introduce RHA® Dynamic Volume for Facial Rejuvenationhttps://modernaesthetics.com/news/revance-teoxane-introduce-rha-dynamic-volume-for-facial-rejuvenation/2486353/Revance and Teoxane have announced the availability of RHA® Dynamic Volume, formerly known as RHA® 4 Mepi, expanding the RHA® Collection with a hyaluronic acid filler designed to adapt to facial movement and support natural-looking outcomes. The product has been approved by the US Food and Drug A
- Study Compares TXA Delivery Methods in Rhinoplasty Outcomeshttps://modernaesthetics.com/news/study-compares-txa-delivery-methods-in-rhinoplasty-outcomes/2486333/In a prospective comparative study published online ahead of print in Journal of Craniofacial Surgery, investigators evaluated the impact of different tranexamic acid (TXA) administration routes on postoperative recovery following implant-based rhinoplasty. A total of 82 patients undergo
- LaserAway Introduces Three New Services Across Its Clinic Networkhttps://modernaesthetics.com/news/laseraway-introduces-three-new-services-across-its-clinic-network/2486088/LaserAway announced the launch of 3 new services across its clinic network: the Salmon DNA Facial, XTherma, and an expanded portfolio of LaserAway Wellness Injections. The company said the additions reflect continued investment in science-backed treatments and its medical-first approach to expand
- Global Study Finds Post-COVID Surge in Cosmetic Procedures, Led by Nonsurgical Fat Reductionhttps://modernaesthetics.com/news/global-study-finds-post-covid-surge-in-cosmetic-procedures-led-by-nonsurgical-fat-reduction/2485998/A global analysis of aesthetic procedure trends suggests the COVID-19 pandemic produced both immediate and sustained shifts in cosmetic procedure demand, with notable regional differences in surgical and nonsurgical treatments.